Vericel Backtesting

Vericel Corporation -- USA Stock  

USD 7.25  0.25  3.33%

With this equity back-testing module your can estimate the performance of a buy and hold strategy of Vericel Corporation and determine expected loss or profit from investing in Vericel over given investment horizon. Also please take a look at Vericel Hype Analysis, Vericel Correlation, Vericel Valuation, Vericel Volatility as well as analyze Vericel Alpha and Beta and Vericel Performance
 Time Horizon     30 Days    Login   to change

Vericel 'What if' Analysis

January 20, 2018
No Change 0.00  0.0%
In 31 days
February 19, 2018
If you would invest  0.00  in Vericel on January 20, 2018 and sell it all today you would earn a total of 0.00 from holding Vericel Corporation or generate 0.0% return on investment in Vericel over 30 days. Vericel is related to or competes with NantKwest, Del Mar, Denali Therapeutics, VBI Vaccines, and Vascular Biogenics. Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sell...

Vericel Upside/Downside Indicators


Vericel Market Premium Indicators

Vericel lagged returns against current returns

 Current and Lagged Values 

Vericel regressed lagged prices vs. current prices

 Current vs Lagged Prices 

Vericel Backtested Returns

Macroaxis considers Vericel risky given 1 month investment horizon. Vericel owns Efficiency Ratio (i.e. Sharpe Ratio) of 0.0878 which indicates Vericel had 0.0878% of return per unit of risk over the last 1 month. Our philosophy towards measuring volatility of a stock is to use all available market data together with company specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for Vericel Corporation which you can use to evaluate future volatility of the company. Please operate Vericel Semi Deviation of 3.91, Coefficient Of Variation of 645.65 and Risk Adjusted Performance of 0.27 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100 Vericel holds performance score of 5. The entity has beta of 1.0488 which indicates Vericel returns are very sensitive to returns on the market. as market goes up or down, Vericel is expected to follow.. Although it is vital to follow to Vericel current price movements, it is good to be conservative about what you can actually do with the information regarding equity historical returns. The philosophy towards measuring future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By inspecting Vericel technical indicators you can presently evaluate if the expected return of 0.3449% will be sustainable into the future. Please operates Vericel Jensen Alpha, Potential Upside as well as the relationship between Potential Upside and Skewness to make a quick decision on weather Vericel existing price patterns will revert.
Advice Volatility Trend Exposure Correlations
15 days auto-correlation 0.35 

Below average predictability

Vericel Corporation has below average predictability. Overlapping area represents the amount of predictability between Vericel time series from January 20, 2018 to February 4, 2018 and February 4, 2018 to February 19, 2018. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Vericel price movement. The serial correlation of 0.35 indicates that nearly 35.0% of current Vericel price fluctuation can be explain by its past prices.
Correlation Coefficient 0.35
Spearman Rank Test 0.28
Price Variance 0.05
Lagged Price Variance 0.15

Vericel Lagged Returns

 Regressed Prices 

Vericel Performance vs DOW

The median price of Vericel for the period between Sat, Jan 20, 2018 and Mon, Feb 19, 2018 is 7.2 with a coefficient of variation of 5.39. The daily time series for the period is distributed with a sample standard deviation of 0.39, arithmetic mean of 7.17, and mean deviation of 0.29. The Stock did not receive any noticable media coverage during the period.
Price Growth (%)